GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...

A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Scientists uncover how TRH neurons suppress hunger by inhibiting AgRP neurons, advancing our understanding of GLP-1-based ...

People are reporting that their weight-loss medication helps them steer clear of drugs and alcohol. Studies are promising, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascula ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Propensity-score matched analysis showed that VTE rates at 1 year were 20% lower for patients starting on a GLP-1 drug rather ...